tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jonas S et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. 1995 Clin Transplant pmid:8541635
Andoh TF et al. Functional and structural characteristics of experimental FK 506 nephrotoxicity. 1995 Clin. Exp. Pharmacol. Physiol. pmid:8542679
Fukunaga T et al. Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. 1995 Acta Orthop Scand pmid:8553828
Ryffel B et al. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. 1995 Immunopharmacology pmid:8557519
Stillman IE et al. FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. 1995 Lab. Invest. pmid:8558840
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Aoyama H et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. 1995 Br. J. Dermatol. pmid:8547017
Klintmalm GB and Gonwa TA Nephrotoxicity associated with cyclosporine and FK506. 1995 Liver Transpl Surg pmid:9346596
Wong PY et al. FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and virus replication. 1995 Liver Transpl Surg pmid:9346613
Coghlan VM et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. 1995 Science pmid:7528941
Marx SO et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. 1995 Circ. Res. pmid:7532117
Clardy J The chemistry of signal transduction. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7529414
Kawai M et al. Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. 1995 J. Immunol. pmid:7532665
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Gonschior AK et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. 1995 Ther Drug Monit pmid:8585114
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Büttemeyer R et al. Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. 1995 Ann Plast Surg pmid:8585683
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Takeda Y et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. 1995 J. Cardiovasc. Pharmacol. pmid:8587392
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Goodall T et al. FK506-induced endothelin release by cultured rat mesangial cells. 1995 J. Cardiovasc. Pharmacol. pmid:8587453
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
Soldin SJ Receptor (immunophilin-binding) assay for immunosuppressive drugs. 1995 Ther Drug Monit pmid:8588223
Armstrong VW et al. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533371
Thomson AW et al. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. 1995 Ther Drug Monit pmid:8588225
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Fung JJ and Starzl TE FK506 in solid organ transplantation. 1995 Ther Drug Monit pmid:8588226
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Jusko WJ Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. 1995 Ther Drug Monit pmid:8588227
Vargas V et al. Alpha-interferon for acute hepatitis C in liver transplant patients. 1995 Transplant. Proc. pmid:7533374
McMaster P et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. 1995 Ther Drug Monit pmid:8588228
Chakraborty TK et al. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand. 1995 Chem. Biol. pmid:9383417
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Ikeda H and Fujiwara K Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. 1995 Hepatology pmid:7535735
Grimmond S et al. Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. 1995 Hum. Genet. pmid:7535744
Jiang H et al. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. 1995 J. Invest. Dermatol. pmid:7535825
Atkison P et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. 1995 Lancet pmid:7535875
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Sheppard KE Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. 1995 J. Neuroendocrinol. pmid:8748119
Iwasaki K et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. 1995 Drug Metab. Dispos. pmid:7536652
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Miranker A and Karplus M An automated method for dynamic ligand design. 1995 Proteins pmid:8749844
Marumo T et al. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. 1995 Hypertension pmid:7536714
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Victor RG et al. Presynaptic modulation of cortical synaptic activity by calcineurin. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7541535
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Elitsur Y et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. 1995 Dig. Dis. Sci. pmid:7555446
Kobayashi I et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. 1995 Eur. J. Pediatr. pmid:7556338
Adachi M et al. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. 1995 FEBS Lett. pmid:7556630
David M et al. [Occurrence of suspicious changes in cervix cytology in women after liver transplantation]. 1995 Geburtshilfe Frauenheilkd pmid:7557217
Woodle ES et al. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. 1995 Clin Transplant pmid:7537988
Mills RA et al. Topical FK-506 prevents experimental corneal allograft rejection. 1995 Cornea pmid:7538061
[Experimental and clinical studies on the effectiveness of new immunosuppressive agents used in heart transplantation and transplantation-related complications]. 1995 Nihon Kyobu Geka Gakkai Zasshi pmid:7561285
Lee TK et al. Postoperative selective bowel decontamination prevents gram-negative bacterial translocation in small-bowel graft recipients. 1995 J. Surg. Res. pmid:7538186
Asano K et al. Generation of effector T cells in Hymenolepis nana-infected, FK-506-treated BALB/c mice. 1995 Immunol. Lett. pmid:7590919
Lam E et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. 1995 J. Biol. Chem. pmid:7592869
Galat A and Metcalfe SM Peptidylproline cis/trans isomerases. 1995 Prog. Biophys. Mol. Biol. pmid:7538221
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Kanda T et al. Synergistic effects of tacrolimus and human interferon-alpha A/D in murine viral myocarditis. 1995 J. Pharmacol. Exp. Ther. pmid:7542339
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Conde M et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. 1995 Immunology pmid:7538492
Skeen MJ and Ziegler HK Activation of gamma delta T cells for production of IFN-gamma is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. 1995 J. Immunol. pmid:7538532
Columbo M et al. Human skin mast cells express functional beta 1 integrins that mediate adhesion to extracellular matrix proteins. 1995 J. Immunol. pmid:7538541
Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. 1995 Biochem. Biophys. Res. Commun. pmid:7544122
Deschler DG et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. 1995 Arch. Otolaryngol. Head Neck Surg. pmid:7544136
Rouvière-Fourmy N et al. 1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein. 1995 Eur. J. Biochem. pmid:7544285
Sakamoto K et al. A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action. 1995 J. Antibiot. pmid:7544337
Natazuka T et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540241
Lee MJ et al. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation. 1995 Immunopharmacol Immunotoxicol pmid:7544367
Dhawan A et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540242
Sauer P et al. In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion. 1995 J. Hepatol. pmid:7544368
Nielsen FT et al. Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. 1995 Nephrol. Dial. Transplant. pmid:7540737
Chang HY et al. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. 1995 Nature pmid:7544441
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Horne SM and Young KD Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. 1995 Arch. Microbiol. pmid:7540828
Teutsch M et al. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin. 1995 Int. Immunol. pmid:7540861
Mori A et al. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. 1995 Int. Immunol. pmid:7540862
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Okamoto M et al. In situ proliferating status of mononuclear cells in rat small bowel grafts. 1995 Int J Exp Pathol pmid:7547442
Platz KP et al. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation. 1995 Clin Transplant pmid:7549052
Hammond TG and Kind CN Pancreatic and nephrotoxicity of immunomodulator compounds. 1995 Toxicol. Lett. pmid:8597171
Mueller AR et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? 1995 Clin Transplant pmid:7549057
Nagai H et al. Effect of some immunosuppressors on allergic bronchial inflammation and airway hyperresponsiveness in mice. 1995 Int. Arch. Allergy Immunol. pmid:7549508
Ma J et al. Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. 1995 Biophys. J. pmid:8599646
Jung-Testas I et al. Cyclosporin A promotes nuclear transfer of a cytoplasmic progesterone receptor mutant. 1995 C. R. Acad. Sci. III, Sci. Vie pmid:7583777
Kissinger CR et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. 1995 Nature pmid:8524402
Lake KD and Canafax DM Important interactions of drugs with immunosuppressive agents used in transplant recipients. 1995 J. Antimicrob. Chemother. pmid:8601538